Summary Perspectives on Financial Model Project OptimusPrime August 31, 2022

Summary Takeaways on Financial Model Provided 8/25 Methodology Management maintains and updates an annual rolling 5-year financial model In light of three major product launches in 2026E, management developed a 10-year P&L projection to account for the Company’s long-term growth opportunity Each product revenue forecast is anchored on historical trends (mix of market size, volume, pricing, penetration) and latest perspectives of product managers Revenue Company’s legacy product, SmartFresh Apple, is expected to steadily erode over time due to pricing pressures from generics entering the market offset by new registrations in new crops and geographies 2026E represents a critical year for growth driven by 1) Harvista approval in Europe and 2) expected launches of Novel Antimicrobials (“BoB”) and Novozymes Biologics Antimicrobials expected to be a large contributor to long-term growth, representing 40%+ of total revenue by 2032E Expenses Diversification products are lower margin in nature vs. SmartFresh Apple. Total gross margin is expected to decline over time as Company executes on its diversification efforts R&D and S&M as a % of revenue largely held flat through 2026E; operating leverage seen primarily from efficiencies within G&A R&D targets 7%-8% of revenue in the near- to medium-term, reflecting continued investment in new product launches Initial diligence session with PWP on 08/29; summary perspectives below:

Key Questions In general, provide context to the process of developing and updating the long-range plan. How is each product line forecasted and validated internally? Provide commentary on the expected erosion of SmartFresh Apple and the factors driving customer retention versus cheaper generics in the market today Discuss risks related to competition within SmartFresh Diversification – should we expect similar erosion if and when generics enter the market? 2026E represents a critical year of growth – please provide commentary on the expected new major product launches of Harvista, Novel Antimicrobial and Novozymes Biologics What is your confidence level in and key risks to achieving the product launch schedule laid out in the plan? Please discuss gross margin evolution as it relates to continued diversification into lower margin products – are there certain products of focus to maintain a higher gross margin? Provide color on operating leverage expected from R&D, S&M and G&A over the forecast period

SmartFresh Apple revenue anticipated to erode over time due to pricing pressures from generics entering the market Antimicrobials projected to be a large contributor to revenue, primarily driven by anticipated Novel Antimicrobial and Novozymes Biologics product launches in 2026 Total gross margin forecasted to decline as Company diversifies into lower margin products R&D and S&M as a % of revenue largely held flat through 2026E; operating leverage seen primarily from efficiencies within G&A Management Finance Case: P&L Source: Company financials ($ in millions) PWP commentary 1 2 3 4 1 2 3 4

Management Finance Case: Revenue and Gross Margin Detail Source: Company financials 1 1 2 Novel Antimicrobials and Novozymes Biologics contribute a large amount to growth and revenue in the outyears Diversification growth products have significantly lower margins than legacy SmartFresh Apple PWP commentary 1 2

Management Finance Case: Cash Flow Statement Source: Company financials ($ in millions)

Management Finance Case: COGS Drivers Source: Company financials

Company TAM Penetration Overview by Selected Products Source: Diligence materials received by Company management on 08/24/22 Note: (1) TAM represents long-term TAM; % penetration represents Company penetration of TAM at maturity (1) Management assumes steady increase in market penetration over time

Company New Product Launch Assumptions Source: Company materials

Legal Disclaimer This Presentation has been provided to you by Perella Weinberg Partners and its affiliates (collectively “Perella Weinberg Partners” or the “Firm”) and may not be used or relied upon for any purpose without the written consent of Perella Weinberg Partners. The information contained herein (the “Information”) is confidential. By accepting this Information, you agree that you and your directors, partners, officers, employees, attorney(s), agents and representatives agree to use it for informational purposes only and will not divulge any such Information to any other party. Reproduction of this Information, in whole or in part, is prohibited. These contents are proprietary and a product of Perella Weinberg Partners. The Information contained herein is not an offer to buy or sell or a solicitation of an offer to buy or sell any corporate advisory services or security or to participate in any corporate advisory services or trading strategy. Any decision regarding corporate advisory services or to invest in the investments described herein should be made after, as applicable, reviewing such definitive offering memorandum, conducting such investigations as you deem necessary and consulting the investor’s own investment, legal, accounting and tax advisors in order to make an independent determination of the suitability and consequences of an investment or service. The information used in preparing these materials may have been obtained from or through you or your representatives or from public sources. Perella Weinberg Partners assumes no responsibility for independent verification of such information and has relied on such information being complete and accurate in all material respects. To the extent such information includes estimates and/or forecasts of future financial performance (including estimates of potential cost savings and synergies) prepared by or reviewed or discussed with the managements of your company and/or other potential transaction participants or obtained from public sources, we have assumed that such estimates and forecasts have been reasonably prepared on bases reflecting the best currently available estimates and judgments of such managements (or, with respect to estimates and forecasts obtained from public sources, represent reasonable estimates). The Firm has no obligation (express or implied) to update any or all of the Information or to advise you of any changes; nor do we make any express or implied warranties or representations as to the completeness or accuracy or accept responsibility for errors. Nothing contained herein should be construed as tax, accounting or legal advice. You (and each of your employees, representatives or other agents) may disclose to any and all persons, without limitation of any kind, the tax treatment and tax structure of the transactions contemplated by these materials and all materials of any kind (including opinions or other tax analyses) that are provided to you relating to such tax treatment and structure. For this purpose, the tax treatment of a transaction is the purported or claimed U.S. federal income tax treatment of the transaction and the tax structure of a transaction is any fact that may be relevant to understanding the purported or claimed U.S. federal income tax treatment of the transaction.